PUBLIC COMPANY
saveTanabe Pharma Corp
updated 4mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
- phase3Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
- phase3Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- phase3Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- phase3Effects of Iron Supplements on the Pharmacokinetics of MT-6548
- phase1The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.
- phase2Exploratory Clinical Study of MT-2301
- phase2A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
🐶 Hiring Signal
News
- Shionogi pays $2B to acquire a rare disease startupThe acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.biopharma_dive · 7h ago
- Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drugNew York City drug developer Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine. To support the restructured company and its Phase 3 trials of a former Tanabe Pharma dr…endpoints · 4d ago
- Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drugAfter vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.fiercebiotech · 7d ago
- Leo Pharma buys rare skin disease drug in $435M dealTanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.biopharma_dive · 1mo ago
- LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugThis is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.biospace · 1mo ago
- Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposureLeo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotec…endpoints · 1mo ago
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 1mo ago
- Mineralys makes money moves before looming hypertension approvalMineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…endpoints · 4mo ago
comments(0)
5-min edit window · permanent after that